About Neurogenic differentiation factor 1
Neurogenic differentiation factor 1 (NEUROD1) is a protein
from Homo sapiens identified by UniProt accession
Q13562, 356 residues long.
MolForge cross-references it against 0 known binders and
335 disease associations.
Target properties
| Protein name | Neurogenic differentiation factor 1 |
| UniProt accession | Q13562 |
| Gene | NEUROD1 |
| Organism | Homo sapiens |
| Length | 356 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (335)
Diseases linked to this target (Open Targets).
- maturity-onset diabetes of the young type 6 · score 0.71
- type 2 diabetes mellitus · score 0.65
- maturity-onset diabetes of the young · score 0.55
- MODY · score 0.53
- neurodegenerative disease · score 0.53
- permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome · score 0.38
- retinitis pigmentosa · score 0.37
- retinopathy · score 0.37
- Retinal dystrophy · score 0.36
- body mass index · score 0.34
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q13562-F1 | alphafold | PREDICTED | 62.11 | — |
Amino-acid sequence (356 residues)
MTKSYSESGL MGEPQPQGPP SWTDECLSSQ DEEHEADKKE DDLETMNAEE DSLRNGGEEE DEDEDLEEEE EEEEEDDDQK PKRRGPKKKK MTKARLERFK LRRMKANARE RNRMHGLNAA LDNLRKVVPC YSKTQKLSKI ETLRLAKNYI WALSEILRSG KSPDLVSFVQ TLCKGLSQPT TNLVAGCLQL NPRTFLPEQN QDMPPHLPTA SASFPVHPYS YQSPGLPSPP YGTMDSSHVF HVKPPPHAYS AALEPFFESP LTDCTSPSFD GPLSPPLSIN GNFSFKHEPS AEFEKNYAFT MHYPAATLAG AQSHGSIFSG TAAPRCEIPI DNIMSFDSHS HHERVMSAQL NAIFHD
Explore Neurogenic differentiation factor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets